Evidence map›Paper›PMID 22795955›Full record

ReviewCytokine2012

Regulating the immune system via IL-15 transpresentation.

Eliseo F Castillo, Kimberly S Schluns

Abstract readReview
In one paragraph

Review in Cytokine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 100 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. IL-15: from discovery to FDA approval.Journal of hematology & oncology · 2025
    Article
  11. Expansion of CD103Frontiers in immunology · 2025
    Article
  12. Article
  13. Article
  14. IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. IL15 and Anti-PD-1 Augment the Efficacy of Agonistic Intratumoral Anti-CD40 in a Mouse Model with Multiple TRAMP-C2 Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Eliseo F CastilloDepartment of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Kimberly S Schluns
The Graduate Center, CUNY · USThe University of Texas MD Anderson Cancer Center · US

Funding

Regulation of memory CD8 T Cell homeostasis by IL-15Ra+R01AI070910 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SCHLUNS, KIMBERLY SUE · 2006 to 2009
$1.5M
NIAID NIH HHS R01 AI070910
6 · The paper itself

Abstract

Transpresentation has emerged as an important mechanism mediating IL-15 responses in a subset of lymphocytes during the steady state. In transpresentation, cell surface IL-15, bound to IL-15Rα is delivered to opposing lymphocytes during a cell-cell interaction. The events most dependent on IL-15 include the development and homeostasis of memory CD8 T cells, Natural Killer cells, invariant Natural Killer T cells, and intraepithelial lymphocytes. As lymphocyte development and homeostasis involve multiple steps and mechanisms, IL-15 transpresentation can have diverse roles throughout. Moreover, distinct stages of lymphocyte differentiation require IL-15 transpresented by different cells, which include both hematopoietic and non-hematopoietic cell types. Herein, we will describe the points where IL-15 transpresentation impacts these processes, the specific cells thought to drive IL-15 responses, as well as their role in the course of development and homeostasis.

Indexed as

AnimalsCD8-Positive T-LymphocytesHumansImmune SystemImmunologic MemoryInterleukin-15Intestinal MucosaNatural Killer T-CellsInterleukin-15

Identifiers

PMID22795955
PMCPMC3422378
OpenAlexW2016067417

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.